[an error occurred while processing this directive]

Herpesviruses Slide Set

Prevention of Cytomegalovirus Infections

 

Prevention

Prevention from CMV infection is desirable in 2 situations ;- (1) in preventing CID of the newborn and (2) infection in susceptible immunocompromised patients.

1. Prevention of Transmission ;- Seronegative renal allograft recipients should be matched to kidneys from seronegative donors. CMV matching has been shown to have a greater effect on the survival of the recipient than HLA class I Ag matching. However, reinfection from seropositive donor kidneys has been shown to cause disease in seropositive recipients. Therefore if seronegative kidneys are given to seronegative patients, then more infected kidneys would be given to seropositive recipients. Seronegative recipients should also receive blood from seronegative donors only.

2. Immunization ;- A live vaccine known as the Towne strain has been reported to be effective in conferring protection or in reducing the severity of disease in seronegative recipients given seropositive kidneys. It was also well tolerated and immunogenic but could not prevent reinfection of the recipients with a different strain of CMV. There were concerns about latency and reactivation of a live vaccine as well as potential oncogenicity. However, there was no evidence of reactivation in immunosuppressed patients or an excess of malignancies. Because of the possibility of reactivation, a live vaccine would be unacceptable for use in seronegative women. Therefore, subunit vaccines are currently being developed based on the membrane proteins SSK and GC1. One encouraging candidate is live vaccine using adenovirus as the vector. This vaccine can be given orally as in the case of adenovirus vaccines used for the protection against adult respiratory distress syndrome. This vaccine is currently being readied for clinical trials.

3. Periexposure Therapy ;- Eventually a suitable anti-CMV drug can be given as prophylaxis against reactivation in susceptible seropositive transplant patients, in as much the same way as acylovir is given to seropositive patients at risk of reactivation of HSV ( when immunosuppressive therapy is given ). It has been reported that acyclovir itself may act prophylactically to reduce CMV infection and disease eventhough it has no role in treatment. Hyperimmune human immunoglobulin has been given in a few trials with encouraging results and also a-interferon has been reported to have some success in renal transplant patients. CMV-hyperimmune globulin and IVIG had been reported to be effective when given to seronegative recipients of solid organ transplants from seropositive patients.

4. Treatment ;- The treatment for an established infection is controversial at present. The drugs ganciclovir and foscarnet have been licensed for use in life threatening CMV infection in immunocompromised patients but have not been subjected to clinical trials. CMV lung infection in AIDS patients is not normally treated because they do not mount the CMI necessary for immunopathology. Immunoglobulin may be given allograft patients with CMV pneumonitis because the antibodies in the preparation may block the immunopathological response to antigens in the lung. The drugs used at present have serious interaction with other drugs eg. ganciclovir and AZT, foscarnet and pentamidine. Moreover, CMV strains resistant to pentamidine have been described.

Site of CMV

Type of patient         Clinical condition         detection             Suggested treatment

Allograft                     None                             Blood                   Ganciclovir or foscarnet

Allograft or AIDS       G.I.                                ulcer Biopsy         Ganciclovir or foscarnet
                                 Retinitis                           Not possible

Allograft                     Pneumonitis                     Lung/blood          Ganciclovir and I.V.immunoglobulin

AIDS                         Pneumonitis                     Lung                     None
 
 

CMV_infection_in_bone_marrow_transplant_recipients
 

Bone marrow transplantation is increasingly used as therapy for aplastic anaemia, various haematological malignancies, immunodeficiency syndromes and thalessaemia. The process involves the ablation of the host's haematopoietic and immune systems and replacement with those of the marrow donor. In BMT patients, every aspect of the immunological function is depleted. The most commonly used donor is a HLA matched sibling. However, related donors who are not fully matched and fully matched but unrelated donors have also been used. Major complications after transplantation include graft versus host disease (GvHD), toxicity from conditioning and infection. Immunosuppression is given for 100 days or more after allogeneic transplant to prevent GvHD, and patients with GvHD are treated with further immunosuppression. Both GvHD and its treatment increases the risk of infection.

BMT recipients are at increased risk of developing severe viral infections, in particular from viruses belonging to the herpesvirus family. CMV is the single most important infection in BMT recipients. CMV infection is the single greatest cause of failure of the transplant and occurs 1 to 3 months following transplantation. It occurs in 30 to 40% of seronegative patients given unscreened blood products and up to 80% of seropositive patients who reactivate latent virus (seropositive recipients of graft taken from seronegative donors are at higher risk than those receiving graft from seropositive donors) 15% of infected patients develop CMV pneumonitis which carries a mortality rate of almost 100% in the past. Once pneumonitis ensues, the clinical course is very rapid. Other manifestations of CMV infection include fever, oesophagitis, colitis, hepatitis, encephalitis retinitis, vasculitis, viraemia and bone marrow failure. The highest mortality occurs 2 to 3 months after the transplant when the patients is out of hospital. There is also a strong association with GvHD but it is uncertain as to which comes first.

It is of utmost importance to reach a diagnosis of active CMV infection early. Urine, saliva, blood and bronchioalveolar lavage specimens may be used for the detection of CMV by cell culture or by a rapid diagnostic method. However, the predictive value of a positive result from different specimens vary. Blood and BAL are reported to have the highest predictive value for severe CMV disease. although they are not as sensitive as urine and saliva specimens. Saliva specimens have the added advantage of being able to yield HSV in case of active HSV infection. Many laboratories appear to have great difficulty in obtaining a positive culture or DEAFF test result from blood specimens.

Cell culture is the gold standard for diagnosing CMV infection but its value is limited by the fact that it takes several days for the characteristic CPE to appear. Rapid diagnostic methods are being increasingly used for the diagnosis of CMV infection, which include rapid culture methods such as the DEAFF test, detection of CMV antigen from polymorphonuclear cells (CMV antigenaemia), and the detection of CMV specific DNA by PCR from white blood cells or serum. The DEAFF test relies on the detection of CMV early antigens 24 to 48 hours following inoculation of the clinical specimen onto cell culture. The CMV antigenaemia test may yield a result several hours within the collection of the specimen but the test is technically tricky to carry out. PCR has been reported to be a valuable method for the diagnosis of CMV viraemia, however its sensitivity must be adjusted so that a positive result can only be obtained from those patients with active CMV infection and not from seropositive individuals with latent CMV infection. The current opinion is that action should be immediately taken on a positive DEAFF test or CMV antigenaemia result from the blood in non-symptomatic individuals. However, two consecutive positive results should be obtained from PCR before action is taken. It is important to standardize the total DNA used in the PCR since BMT patients typically have a very low concentration of white cells.

Several protocols have been described for the monitoring of active CMV infection in BMT recipients. Surveillance urine and/or saliva and/or blood specimens are taken either weekly or twice weekly. BALs may be performed routinely in all recipients 1 month after transplant or in the presence of clinical symptoms. There are four main strategies for the use of antiviral agents against CMV in BMT recipients;-

1. Prophylaxis - treatment is given before and for a certain period after transplant

2. Suppression - treatment is given if CMV excretion is found at any site

3. Pre-emptive treatment - treatment is given if CMV were isolated from BAL or blood

4. Treatment of established disease.

CMV hyperimmune globulin, acyclovir and ganciclovir had been used for prophylaxis against CMV in BMT recipients with varying degrees of success. The current opinion is that acyclovir is of some value although this has been questioned recently. Although ganciclovir prophylaxis had been shown to reduce CMV infection, it is probably too toxic for use in the routine prophylaxis of bone marrow transplantation, except perhaps for matched unrelated donor (MUD) transplants. Suppression using ganciclovir had been described for one clinical trial and was reported to have a significant effect on the reduction of CMV disease. However, current opinion is not in favour of giving treatment with ganciclovir if CMV excretion is detected from the urine or saliva. Instead, consideration should be given to the relaxation of immunosuppression. Preemptive treatment with ganciclovir is now routinely given in many centres if CMV is detected from BAL or blood. Clinical trials have shown that ganciclovir reduced the development of CMV pneumonitis and death. Once CMV pneumonitis or other CMV disease is established, treatment is difficult. CMV hyperimmune globulin in conjunction with ganciclovir had been shown to have some benefit in established cases of CMV pneumonitis.

It is recognized that different types of BMT carry different levels of risk for severe CMV disease. Patients undergoing autologus transplants are at the lowest risk. Patients receiving allogeneic transplants from matched sibling are at a much increased risk, while those who have received marrow from a matched unrelated donor (MUD) are at the highest risk (since minor histocompatibility antigens are extremely unlikely to be matched in this case). Therefore, some BMT units are giving ganciclovir prophylaxis for all MUD transplants.
 

CMV_Infection_in_Solid Organ Transplant Recipients
 

Renal Transplants

CMV infection is ubiquitous in renal transplant patients, occurring in up to 80% of all patients and is the most common pathogen. Most of these infections are due to reactivation and are asymptomatic. Primary infection occurs less commonly but account for the majority of clinical CMV disease. Clinical CMV disease may comprise of fever, leukopenia, pneumonitis, retinitis, enteritis, hepatitis and encephalitis. CMV infection also leads to acute deterioration in graft function and it may also result in immunosuppression and thus allowing infection by other opportunistic agents. Seronegative patients who receive transplants from seropositive donors are at the greatest risk of developing CMV disease. Patients who are seropositive for CMV are also at risk, with 20 to 30% developing clinical illness, infection resulting either from reactivation or reinfection with another strain of CMV. There is no evidence to suggest that CMV directly causes allograft rejection or glomerulonephritis although patients with CMV disease have higher rates of allograft loss. As in the case of bone marrow transplants, viraemia is the best prognostic indicator of clinical CMV disease.

Interferon, high dose acyclovir, CMV-specific immunoglobulin for seronegative patients given grafts from seropositive donors had been reported as effective prophylaxis measures in reducing clinical CMV disease. Donor-recipient CMV antibody status matching is desirable. Although the efficacy of high dose acyclovir and hyperimmune globulin had been questioned recently. The use of a -interferon had been associated with frequent irreversible rejection reactions and should not be used. Pre-emptive treatment with ganciclovir should be considered for those at high risk of progression to symptomatic CMV disease such as those with viraemia or seropositive recipients receiving antilymphocyte serum.
 

Heart_transplants

Primary and recurrent CMV infection occurs in heart and heart- lung transplant recipients. Most fatal CMV infections arise in seronegative recipients of hearts from seropositive donors. CMV infection is more severe when acquired from the donor organ than blood or blood products. Those CMV antibody-positive recipients who received organs from seropositive donors were reported to have more severe recurrent CMV disease than those who received organs from CMV seronegative donors. The severity of CMV disease is dependent on the degree of immunosuppression and heart-lung transplant recipients had more serious CMV disease than heart transplant patients. CMV donor-recipient matching is carried out if possible. The use of CMV hyperimmune globulin as a prophylaxis was found to have a beneficial effect, although primary infection was not prevented, the severity of infection was reduced. Ganciclovir had also been used as a prophylactic agent in a recent clinical trial and was reported to have significant clinical benefit. The role of acyclovir is uncertain. Pre-emptive treatment with ganciclovir should be considered for those at high risk of progression to symptomatic CMV disease such as those with viraemia.
 

Liver_transplant_recipients

CMV infection is a major cause of morbidity and mortality following liver transplantation. Both primary and recurrent infection are common. Risk factors include donor seropositivity, the use of antilymphocyte preparations, and re-transplantation. Liver is the most involved organ, followed by the lung, the GI tract, and the retina. Donor-recipient CMV antibody status matching is recommended. CMV hyperimmune globulin had been reported as an effective form of prophylaxis, although it had been reported to have no effect on the highest risk group, namely the R-D+ group. Acyclovir had been tried as prophylaxis and had been reported to have little value. Ganciclovir prophylaxis may be of some value.
 

Post-transplant surveillance

The current feeling is that routine post-transplant surveillance is not necessary for most solid organ transplant recipients. This is because even though CMV infection is just as common as in BMT patients, the disease manifestation rate is much lower, and even if disease is present, it is much more manageable than in BMT patients. However, routine surveillance should be considered for those at particularly high risk eg. on high dose steroids or other immunosuppression.
 

[an error occurred while processing this directive]

Herpesviruses Slide Set